Aurobindo Pharma Limited

NSE: AUROPHARMA

61

total announcements

AUROPHARMA.NS · 15 min delayed

Key Stats · Yahoo Finance · as of 14 Oct 2026

Market Cap

₹96,928 Cr

P/E (TTM)

26.5

P/E (Forward)

18.0

EPS (TTM)

₹63.48

52W Low

₹1,080.10

52W High

₹1,740.00

Dividend Yield

0.00%

Beta

0.03

Price / Book

2.6

Debt / Equity

21.3

Revenue (TTM)

₹34,935 Cr

Gross Margin

58.85%

Operating Margin

15.24%

AnnouncementsDiscussion
NSEGeneral Updates19 Jun 2026

Aurobindo Pharma Limited

General Updates

Aurobindo Pharma Limited has announced that it has received the necessary approval from the US Federal Trade Commission (FTC) for its acquisition of the Lannett business. This approval pertains to Aurobindo Pharma USA Inc., a wholly-owned subsidiary, acquiring 100% of the membership interest in Lannett Company LLC. This marks a crucial step forward for the previously announced acquisition. For investors, this signifies the removal of a major regulatory hurdle, paving the way for the completion of the transaction.

Read more →📎 1 attachment
← PreviousPage 4 of 4